pharm 9: nucleic acid inhibitors

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/65

encourage image

There's no tags or description

Looks like no tags are added yet.

66 Terms

1
New cards

Nucleic acid inhibitor classes

Fluoroquinolones (DNA gyrase inhibitors), sulfonamides and potentiated sulfonamides (folic acid synthesis inhibitors), nitroimidazoles (toxic metabolite production), rifampin (inhibits DNA-dependent RNA polymerase); all work on nucleic acid synthesis via very different pathways

2
New cards

Fluoroquinolones labeled for dogs

Enrofloxacin (Baytril), marbofloxacin (Zeniquin), orbifloxacin (Orbax), difloxacin (Dicural)

3
New cards

Fluoroquinolones labeled for cats

Marbofloxacin, orbifloxacin, pradofloxacin (Veraflox)

4
New cards

Fluoroquinolones labeled for cattle

Enrofloxacin (Baytril 100), danofloxacin (Advocin), pradofloxacin (Pradalex)

5
New cards

Fluoroquinolones labeled for swine

Enrofloxacin (Baytril 100) and pradofloxacin (Pradalex)

6
New cards

Fluoroquinolones in poultry

Products were pulled from the market

7
New cards

Fluoroquinolones in horses

Used off-label: enrofloxacin, and occasionally marbofloxacin

8
New cards

Ciprofloxacin

Used off-label in dogs only (cheap); poorly absorbed in cats and really poorly absorbed in horses

9
New cards

Fluoroquinolone extralabel use

Prohibited in food animals

10
New cards

Fluoroquinolone mechanism of action

Inhibit DNA gyrase (topoisomerase II), required for bacterial DNA replication, transcription, repair, and recombination

11
New cards

Newer-generation fluoroquinolone mechanism

Also inhibit topoisomerase IV (pradofloxacin)

12
New cards

Fluoroquinolone activity

Bactericidal with a post-antibiotic effect

13
New cards

Fluoroquinolone spectrum

Gram-negative aerobes (enteric/BRDC) and staphylococci; similar to aminoglycosides but safer in azotemic patients (kidneys)

14
New cards

Fluoroquinolone activity against Pseudomonas

Some activity, use with caution; higher doses often needed (topical) and resistance can develop during treatment (especially enrofloxacin)

15
New cards

Other fluoroquinolone targets

Brucella, Legionella, Chlamydia, Leptospira, and sometimes Mycobacteria

16
New cards

Fluoroquinolone gaps

Poor against streptococci and not active against enterococci

17
New cards

Pradofloxacin spectrum

Best activity against anaerobes and better against gram-positive aerobes

18
New cards

Fluoroquinolone oral absorption

Well absorbed orally in monogastrics

19
New cards

Fluoroquinolone absorption exceptions

Ciprofloxacin is poorly absorbed in cats and horses; enrofloxacin is not given orally to kittens on a milk diet (chelation)

20
New cards

Fluoroquinolone distribution

Distribute well to tissues, penetrate well intracellularly and across barriers; enrofloxacin has the highest lipid solubility and volume of distribution

21
New cards

Enrofloxacin metabolism

Metabolized in vivo to the active metabolite ciprofloxacin (the only fluoroquinolone with this); species and age dependent

22
New cards

Enrofloxacin conversion to ciprofloxacin by species

41% cattle, 36% dogs, 17% horses, 0% foals, 16% kittens

23
New cards

Fluoroquinolone elimination

Mainly renal; exception is pradofloxacin (hepatic elimination)

24
New cards

Fluoroquinolone dosing interval

Moderate half-life; once daily due to the PAE (exception: twice daily ciprofloxacin in dogs)

25
New cards

Fluoroquinolone PK/PD

Concentration-dependent (concentration/time dependent); AUC24h:MIC ratio with a target of about 72 (higher than older guidelines)

26
New cards

Fluoroquinolone GI adverse effects

Rarely vomiting, diarrhea, abdominal pain in dogs and cats

27
New cards

Fluoroquinolone CNS toxicity

High doses or rapid IV administration cause CNS excitement, confusion, or seizures through inhibition of GABA; do not use in epileptic patients

28
New cards

Pradofloxacin adverse effect

Bone marrow suppression in dogs (and cats)

29
New cards

Ciprofloxacin in horses

Causes fatal colitis (PO or IV)

30
New cards

Fluoroquinolone cartilage toxicity

Severe; chelation of Mg++ in cartilage decreases chondrocyte adherence (possibly tendons and ligaments too)

31
New cards

Fluoroquinolone cartilage risk by age

Neonatal and young foals are most affected: young, large (35-80 kg), prey animals that run a lot, often sick (7-14 days of treatment); younger and heavier means more severe damage

32
New cards

Fluoroquinolone cartilage risk in other species

Any neonatal or young animal until cartilage is fully developed; concern with large and working breed dogs

33
New cards

Fluoroquinolone ocular toxicity in cats

Enrofloxacin is the main cause; dose dependent retinal degeneration and irreversible blindness (defective drug transporters)

34
New cards

Fluoroquinolone drug interactions

May inhibit clearance of some drugs (e.g., theophylline); chelation with antacids, sucralfate, and multivitamins (iron), so do not give orally at the same time

35
New cards

Fluoroquinolone resistance mechanisms

Alteration of the target enzyme (DNA gyrase) and reduced access through altered porins (Pseudomonas; resistance may develop during treatment, especially with enrofloxacin)

36
New cards

Fluoroquinolone key concepts

Broad spectrum (gram-negatives and staph), DNA gyrase inhibition and bactericidal, AUC:MIC, extralabel use prohibited in food animals, cartilage damage in the young (especially foals), retinal toxicity in cats (especially enrofloxacin), ciprofloxacin only for dogs

37
New cards

Sulfonamides approved for food animals

Sulfamethazine, sulfadimethoxine, sulfaquinoxaline, sulfachlorpyridazine (for testing, "sulfas are sulfas"; no need to memorize names)

38
New cards

Sulfonamide extralabel use

Prohibited in adult dairy cattle

39
New cards

Potentiated sulfonamide

A sulfonamide plus a dihydrofolate reductase inhibitor (DHFRI, a diaminopyrimidine)

40
New cards

Trimethoprim-sulfadiazine

Horses (and swine): Uniprim, Tucoprim, Equisul-SDT

41
New cards

Pyrimethamine-sulfamethoxazole

Horses for EPM: ReBalance

42
New cards

Ormetoprim-sulfadimethoxine

Dogs (and cats): Primor

43
New cards

Potentiated sulfonamides in companion animals

Used in companion animals and extralabel in swine

44
New cards

Sulfonamide and DHFRI activity alone

Each alone is bacteriostatic

45
New cards

Sulfonamide + DHFRI activity

Bactericidal (synergism, "potentiated")

46
New cards

Why use a sulfonamide alone

In ruminants, which do not absorb DHFRIs (it would just sit in the GI tract)

47
New cards

Sulfonamide mechanism of action

Inhibit dihydropteroate synthase, blocking conversion of PABA to dihydropteroic acid (folic acid synthesis)

48
New cards

DHFRI mechanism of action

Inhibit dihydrofolate reductase, blocking dihydrofolic acid to tetrahydrofolic acid; ultimately blocks thymidine synthesis (a component of DNA)

49
New cards

Why potentiated sulfonamides are safe for mammals

Mammals use dietary folate and do not require PABA; bacterial dihydrofolate reductase has 50,000-60,000 fold higher affinity for trimethoprim than mammalian DHFR

50
New cards

Potentiated sulfonamide spectrum

Broad spectrum covering all 4 quadrants; effective against protozoa; may work in some MRSA/MRSP; in vitro anaerobic susceptibility does not translate in vivo (not used clinically for anaerobes)

51
New cards

Potentiated sulfonamide uses

First-line for pyodermas, UTIs, and soft tissue infections if susceptible; one of the only safe oral options for horses (resistance is increasing, especially in horses)

52
New cards

Potentiated sulfonamide PK

Well absorbed orally; good tissue distribution (extracellular and intracellular); sulfadiazine and pyrimethamine best (including CNS and prostate); extensive hepatic metabolism; moderate half-life (once or twice daily); mainly renal elimination

53
New cards

Potentiated sulfonamide PK/PD

Time-dependent

54
New cards

Potentiated sulfonamide toxicity: horses

Minimal (occasional diarrhea); cheap

55
New cards

Potentiated sulfonamide toxicity: cats

Minimal; taste and difficulty pilling (slobbering)

56
New cards

Potentiated sulfonamide toxicity: ruminants and swine

Safe

57
New cards

Potentiated sulfonamide toxicity: dogs

The problem species; dogs lack N-acetyltransferase (detoxifying enzyme), so toxic metabolites are produced

58
New cards

Potentiated sulfonamide breed risks in dogs

Doberman Pinschers (hypersensitivity reactions, cytochrome b5 reductase), possibly Rottweilers; also Samoyeds and Miniature Schnauzers

59
New cards

Potentiated sulfonamide immune reactions in dogs

Polyarthropathy, polymyositis, lymphadenopathy, fever, glomerulonephropathy, focal retinitis, hemolytic anemia; typically reversible, idiosyncratic, onset 5-36 (mean 12) days; not really reported in other species

60
New cards

Potentiated sulfonamide cutaneous reactions in dogs

Range in severity and typically reversible (most common ADR in one study); includes Stevens-Johnson syndrome and toxic epidermal necrolysis (blistering and ulceration across the body, protein loss, can be fatal)

61
New cards

Potentiated sulfonamide hepatopathy and thrombocytopenia

Lower recovery rate; possibly dose-dependent ADR

62
New cards

Potentiated sulfonamide keratoconjunctivitis sicca

Possible toxic effect on the lacrimal gland, typically after prolonged administration (may occur after short periods); may not be reversible, so discontinue early; possible in horses

63
New cards

Potentiated sulfonamide hypothyroidism

Block formation of thyroxine and thyronine; reversible, usually disappears within 3 weeks of discontinuation; can affect thyroid hormone testing; avoid in animals already diagnosed as hypothyroid

64
New cards

Potentiated sulfonamide bone marrow suppression

Rare in any species; secondary to folate antagonism with long-term dosing; combining DHFRIs increases risk (e.g., EPM treatment with trimethoprim plus pyrimethamine)

65
New cards

Potentiated sulfonamide urinary crystals

Rare in any species; precipitation of sulfonamide in acidic urine (older formulations); ensure adequate hydration

66
New cards

Should we use TMS in dogs?

Yes, judiciously: 31 studies of 3,776 dogs showed mild adverse events in 2% and severe in 0.2%; 23 fewer adverse events per 1000 treated dogs than other antimicrobials; keratoconjunctivitis prevalence about 1.8% in 2,243 treated dogs